Recursion Pharmaceuticals (RXRX) Stock Surges After Beating Q4 Estimates
Recursion Pharmaceuticals (RXRX) shares rallied sharply following a stronger-than-expected fourth-quarter performance. The AI-driven drug developer reported a loss of $0.21 per share, surpassing the consensus estimate of a $0.30 loss. Revenue soared to $35.54 million, far exceeding the $24.51 million forecast, fueled by a $30 million milestone payment from Roche.
Full-year revenue climbed 27% year-over-year to $74.7 million, bolstered by strategic acquisitions. With $743.3 million in cash reserves, the company maintains financial flexibility through 2028. The results underscore Recursion's growing traction in biopharma partnerships and AI-enabled drug discovery.